Skip to content

Issue 2:2 of Cancer Medicine now live!

April 18, 2013

Cancer Medicine

You can read Issue 2:2 of Cancer Medicine online now!

The journal brings together articles on a range of oncology specialties, covering cancer biology, clinical cancer research and cancer prevention, with authors from across the globe.

Below are some top articles which Editor-in-Chief Prof. Qingyi Wei has highlighted from the issue.  We hope that you enjoy this exciting new content.

purple_lock_open

GM-CSF enhances tumor invasion by elevated MMP-2, -9, and -26 expression
Claudia M. Gutschalk, Archana K. Yanamandra, Nina Linde, Alice Meides, Sofia Depner and Margareta M. Mueller

Summary: In this study we analyze the contribution of granulocyte–macrophage colony-stimulating factor (GM-CSF) to tumor invasion and proteinase expression and activation in HT-29 colon adenocarcinoma cells. We could demonstrate that GM-CSF contributes to tumor progression, enhancing the migratory capacity in vitro and tumor cell invasion into the surrounding tissue and stromal activation such as angiogenesis in vivo. Moreover, in a complex 3D in vitro model, GM-CSF overexpression or treatment was associated with a discontinued basement membrane deposition that might be mediated by the observed increased expression and activation of MMP-2, -9, and -26.

purple_lock_open

Complexity in cancer biology: is systems biology the answer?
Evangelia Koutsogiannouli, Athanasios G. Papavassiliou and Nikolaos A. Papanikolaou

Summary: Tumor tissues consist of different types of cells with altered genetic, epigenetic, and protein networks. We propose a simple conceptual model to account for oncogenic and tumor suppressor proteins forming different complexes within and between tumor cells.

purple_lock_open

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
Edward Cha and Eric J. Small

Summary: Ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking monoclonal antibody, is thought to augment natural immune responses to tumors. Ipilimumab is approved in several countries to treat advanced melanoma, and it is now under phase 3 investigation in prostate cancer based on the results of 7 smaller clinical trials, as reviewed in this article.

Cancer Medicine is a peer reviewed, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences.

Submit your paper here>    Sign up for eToC Alerts here>

Advertisements
No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: